Hims & Hers Health, Inc. (HIMS)
Hims & Hers Stock Is On Fire, But Is It a Bubble?
Shares of Hims & Hers (HIMS -0.96%) stock are up nearly 500% in the past year, but is the stock in bubble territory, or is there still growth ahead? Travis Hoium tackles that question plus the company's high short interest in this video.
What Is Driving Hims & Hers Stock Higher?
In this video, I will talk about recent updates regarding Hims & Hers Health (HIMS -1.85%). Watch the short video to learn more, consider subscribing, and click the special offer link below.
Hims & Hers Stock Jumps 156.9% in Three Months: What's Next?
HIMS is enhancing offerings and expanding its health and wellness products and services to solidify its footing. However, macro challenges are likely to hurt its performance.
Hims & Hers: From Viral Ad to Volatile Stock
Hims & Hers Health's NYSE: HIMS share price has surged recently, climbing above $60 and creating new 52-week and all-time record highs for the company. This significant increase in Hims & Hers Health's stock price has attracted considerable attention from investors.
Hims & Hers Health Stock: A Millionaire-Maker in the Making?
Shares of direct-to-consumer telehealth platform Hims & Hers Health (HIMS 2.18%) have become a runaway freight train. The stock has returned nearly 20-fold returns from its 2022 lows, including a blistering 490% over the past year alone.
Hims & Hers Health, Inc. (HIMS) Ascends While Market Falls: Some Facts to Note
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $60.30, signifying a +1.88% move from its prior day's close.
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Buy, Sell, Or Hold HIMS Stock At $60?
The stock price of Hims & Hers Health (NYSE: HIMS), a telehealth platform, has surged an impressive 43% over the past week. A major driver of this growth was the company's widely discussed Super Bowl commercial, which aired on Sunday.
Hims & Hers Health (HIMS) Surges 27.7%: Is This an Indication of Further Gains?
Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why Hims & Hers Terrifies Big Pharma
Hims & Hers (HIMS 1.82%) launched a Super Bowl ad this week, and everyone from pharmaceutical companies to pharmacists tried to block it. Travis Hoium explains why that's a great sign that the company's disruptive potential is real.
Hims & Hers Health: Explosive Growth Potential Ahead
Hims & Hers has shown significant growth, with a 350% stock gain in 2024, driven by subscriber and revenue increases, and positive free cash flow. The company boasts a strong balance sheet with $250M in cash, no debt, and strategic share repurchases, enhancing shareholder value. Future growth is expected from personalized solutions, with the potential to expand the subscriber base by millions and grow revenue per subscriber.
Why Hims & Hers Health Stock Crushed Novo Nordisk and Viking Therapeutics Today
Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The decliners were Novo Nordisk (NVO -2.90%), famously the company behind Wegovy, and Viking Therapeutics (VKTX -7.34%), which is far along in its development of an advanced GLP-1-based obesity treatment.
